May 10, 2021

The highly prestigious medical journal The Lancet published the results of Aurinia’s Phase 3 AURORA 1 study testing Lupkynis™ (voclosporin) in adults with lupus nephritis. Lupkynis was approved by the U.S. Food and Drug Administration based on these data. The AURORA 1 study results showed that Lupkynis in combination with the commonly used mycophenolate mofetil (MMF) and low-dose corticosteroids significantly raised the rate of response compared with mycophenolate mofetil and low-dose corticosteroids alone.

The published AURORA 1 results are based on the global Phase 3 randomized, double-blind, placebo-controlled study (NCT03021499) designed to evaluate the efficacy and safety of Lupkynis (23.7 mg twice daily) when added to  MMF and low-dose corticosteroids, compared to background therapy alone in an ethnically and racially diverse patient population with active LN.

Source: Aurinia Pharmaceuticals Inc. Press Release May 10, 2021, 6:05 AM

In addition, the company issued a press release affirming its commitment to increasing access to equitable healthcare for individuals living with lupus and lupus nephritis through the sponsorship of grants to establish community-focused patient navigator programs. “The grant awards aim to ensure that patients are educated about the importance of routine screenings and medical appointments; that patient’s basic needs are met; and that patients are connected with the resources needed to receive ongoing treatment and medical care.”

Source: Aurinia Pharmaceuticals Inc. Press Release May 10, 2021, 4:05 PM